Clinical Trial Update: Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study assessing genomic and proteomic analyses of docetaxel and capecitabine used as primary chemotherapy for stage II-III breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED